Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Canntab Therapeutics Limited (C:PILL)

Business Focus: Alternative Medicine

Sector:  Healthcare Industry:  Pharmaceuticals
 
Company Contact
Address: 411 Cranbrooke Avenue
TORONTO ON M4M 1N4
Tel: N/A
Website: N/A
IR: N/A
Key People
N/A    
Business Overview
Canntab Therapeutics Limited is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The Company's operations comprise a single segment engaged in the medical marijuana business. The Company's hard pill cannabinoid formulations provide doctors, patients, and consumers with medical grade solutions. These include once a day and extended-release formulations. Its products include INSTANT RELEASE - (IR Tablet), EXTENDED-RELEASE - (XR Tablet), and ORAL DISSOLVING - O.D. Tablet (ODT). The IR Tablet is a release profile for solid hard tablets. The XR Tablet is a phytocannabinoid vehicle that is designed to directly address the drawbacks and challenges of competing oral delivery systems. ODT is specifically designed to dissolve directly in the patient's mouth, with an onset of action between five and thirty minutes.
Financial Overview
For the nine months ended 28 February 2023, Canntab Therapeutics Ltd revenues decreased 87% to C$34K. Net loss decreased 15% to C$1.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Employee compensation and benefits decrease of 58% to C$326K (expense), Professional fees decrease of 75% to C$138K (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $1.34M as of Feb 28, 2023
Annual revenue (TTM): $0.07M as of Feb 28, 2023
EBITDA (TTM): -$1.59M as of Feb 28, 2023
Net annual income (TTM): -$3.36M as of Feb 28, 2023
Free cash flow (TTM): -$1.43M as of Feb 28, 2023
Net Debt Last Fiscal Year: $1.88M as of Feb 28, 2023
Shares outstanding: 38,909,159 as of Mar 7, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization